FDA Asks Lilly, Novo to Remove Suicide Warnings From GLP-1 Labels
The FDA has asked Eli Lilly and Novo Nordisk to remove suicide‑related warnings from the labels of their GLP‑1 weight‑loss drugs. The warning, added in 2022 after isolated case reports, is being reconsidered following a thorough review of post‑marketing data. The agency concluded that current evidence does not establish a causal link between the drugs and suicidal behavior. Consequently, the manufacturers will revise prescribing information for products such as Ozempic, Wegovy and Mounjaro.
HHS Ousts Vaccine Injury Panel Members as Reshaping Takes Hold
The U.S. Department of Health and Human Services removed several members from the Vaccine Injury Compensation Program’s advisory committee, signaling a significant reshaping of the panel. The ousted members were appointed during the previous administration and faced criticism for their...
Charles River Laboratories Acquires PathoQuest and K.F. (Cambodia)
Charles River Laboratories exercised its option to buy the remaining 79% of PathoQuest for roughly $60 million, completing its 2018 investment. The Paris‑based firm brings next‑generation sequencing (NGS) capabilities that accelerate in‑vitro GMP and non‑GMP biologics testing while supporting alternative methods...
Trump Administration Appears to Have Ended Its US Trade Probe Into Pharma
The U.S. Department of Commerce has reportedly concluded its Section 232 investigation into pharmaceutical imports, effectively ending the Trump administration’s trade probe. The decision means no new tariffs will be levied on foreign‑made medicines, averting a potential price shock for...
TAC to the Future: Where Induced Proximity Is Pointing in 2026
The targeting chimera (TAC) platform is shifting from early‑stage proof‑of‑concept to broader industry adoption as 2026 approaches. Companies are deploying next‑generation E3 ligases, cell‑surface degrader formats, and non‑proteolytic proximity mechanisms to expand target space beyond intracellular proteins. These advances promise...
Researchers Urge Unified Approach to Sustainable Agriculture Innovation and Policy Reform
Researchers at the University of Bonn’s PhenoRob Cluster argue that Europe’s agriculture must shift from isolated fixes to a unified, vision‑led innovation system. Their paper in Agricultural Systems outlines how coordinated technology, business models, and policy reforms can make farming...
VantAI Gets $80M and New Name; Dynavax Discloses It Had Pre-Sanofi Suitor
VantAI, a Roivant‑incubated AI drug‑discovery startup, closed an $80 million seed round and announced a rebrand to Proxima. The funding, led by existing backers, is intended to accelerate its proprietary AI platform for early‑stage therapeutics. The round underscores growing investor appetite...
Who’s Afraid of OpenAI?
OpenAI’s accelerating pace of model development is prompting businesses to reconsider direct competition. Companies are weighing whether to build in‑house AI, partner with OpenAI, or adopt alternative strategies. The debate intensifies as OpenAI’s products become more embedded in enterprise workflows,...
Harnessing the Medicinal Benefits of Thyme Extract via Nanodosing
Russian researchers from Tomsk Polytechnic and Surgut State Universities have demonstrated a microfluidic technique that encapsulates thyme extract in gelatin‑alginate nanodroplets within an oil carrier. The process creates self‑regulating nanodoses, preventing rapid evaporation and skin irritation associated with raw thyme...
Morphological Anomalies Found in Japanese Haemaphysalis Ticks
Japanese researchers have documented the first morphological anomalies in the tick species Haemaphysalis megaspinosa, publishing detailed findings in Acta Parasitologica. The study reports malformed legs, irregular scutum patterns, and atypical mouthpart development, challenging the long‑held view of the species' morphological...
Digital Health Funding Increases in 2025, Spurred by AI: Report
Digital health funding jumped to $14.2 billion in 2025, the highest level since 2022, driven largely by artificial‑intelligence startups. AI‑focused firms secured 54% of total capital and enjoyed a 19% premium in average deal size versus non‑AI peers. Although the total...
Open-Source Robotic System Cuts Manual Cell Culture Time by 61% While Boosting Seeding Consistency
Researchers unveiled the Automated Cell Culture Splitter, an open‑source system built around the Opentrons OT‑2 robot and a custom cell‑counting imager. In tests with HEK293T cells, the platform cut hands‑on passaging time by 61% and delivered a 92% usable imaging...
What Sanofi’s Multiple Sclerosis Troubles Could Mean for the Space
Sanofi’s BTK inhibitor tolebrutinib failed pivotal late‑stage trials in both relapsing and primary progressive multiple sclerosis, prompting the FDA to reject its approval over liver toxicity concerns. The setback highlights the challenges of BTK‑targeted therapies, even as competitors like Roche’s...
Pharmaceutical Supply Chain Resilience in a Shifting Market
Pharma companies are curbing investment amid pricing pressure and growth anxiety, creating a self‑fulfilling slowdown. To protect against supply disruptions, firms are auditing entire supply chains, adding second and third sources, and holding safety stock, which ties up cash. Geographic...
Seven Biotech Companies to Know in the Netherlands
The Netherlands hosts a dense biotech ecosystem anchored by hubs such as Leiden Bio Science Park, which supports over 400 firms and 25,000 jobs. Seven standout companies illustrate the country’s breadth, from Leyden Labs’ intranasal antibody sprays to Merus’ bispecific...
After Mortality-Marred Year, Sarepta Looks Ahead to Catalyst-Rich 2026
Sarepta Therapeutics is shifting focus from a troubled DMD gene‑therapy portfolio to a robust siRNA pipeline partnered with Arrowhead. Jefferies highlights upcoming Phase I/II data for SRP‑1001 (FSHD) and SRP‑1003 (DM1) in Q1 2026, projecting a potential 25‑50% stock move. The...
AI Innovations Transform Glioma Diagnosis and Treatment
Artificial intelligence platforms are now integrating multimodal imaging, genomics, and clinical data to improve glioma diagnosis and personalize treatment plans. Recent trials show AI‑driven segmentation reduces radiologist workload by 40% and predicts tumor grade with 92% accuracy. Companies such as...
Lung Cancer Trial to Proceed After FDA Releases Hold on Merck, Daiichi’s ADC
The U.S. Food and Drug Administration has lifted the partial clinical hold on Merck and Daiichi Sankyo’s antibody‑drug conjugate ifinatamab deruxtecan (I‑DXd) in the Phase III IDeate‑Lung02 trial for relapsed small‑cell lung cancer. The companies can now resume enrollment and data...
Marea Takes Drug for Acromegaly to Phase 2
Marea Therapeutics announced that its experimental drug for acromegaly has entered Phase 2 clinical testing. The move follows CEO Josh Lehrer’s October 2023 appointment and a review that revealed the compound had not met earlier expectations in pre‑clinical models. The Phase 2...
Superorganism Raises $25M to Back Biodiversity Startups
Superorganism, launched in 2023, closed its inaugural fund with $25.9 million from investors including the Cisco Foundation and Andreessen Horowitz partner Jeff Jordan. The firm will write $250,000‑$500,000 checks for pre‑seed and seed‑stage biodiversity startups and donate 10 % of profits to...
Global Autism: Risks, Burden, and Implications Uncovered
A 2026 Pediatric Research study by Saad et al. merges worldwide epidemiological data with molecular profiling to map Autism Spectrum Disorder’s (ASD) prevalence, risk factors, and economic impact. The analysis reveals a global prevalence of roughly 1.2%, with marked regional...
Novartis Licenses Radiopharma Asset From Chinese Biotech for $50M Upfront
Novartis has agreed to pay $50 million upfront to license a peptide‑based radiopharmaceutical asset from China’s Zonsen PepLib Biotech. The agreement, announced Monday, adds a novel imaging candidate to Novartis’ growing portfolio of radiopharma programs. Zonsen PepLib, a biotech focused on...
#JPM26: Day 2 at the JP Morgan Healthcare Conference
Amgen announced on day two of the J.P. Morgan Healthcare Conference that its experimental long‑acting obesity injection, Maritide, met primary endpoints in a Phase 2 trial. The data showed statistically significant weight loss and favorable safety signals in patients with obesity....
AbbVie Turbocharges Its US Investment Promise to $100bn
AbbVie has signed a most‑favoured‑nation pricing deal with the Trump administration, committing $100 billion to U.S. research, development and manufacturing over the next ten years. The agreement mirrors those of 16 other large pharma firms and secures an exemption from potential...
Sentynl Gets the First US Approval for Rare Copper Absorption Disease
Sentynl Therapeutics announced that the U.S. Food and Drug Administration has granted approval for its investigational therapy targeting Menkes disease, a rare and fatal genetic disorder of copper absorption. The approved product, branded Zycu..., is the first therapy in the...
Maternal Vitamin K Intake Shapes Early Brain Development
New research shows that maternal vitamin K consumption during pregnancy significantly influences early brain development in offspring. The study, involving longitudinal imaging and cognitive testing of 1,200 infants, found higher maternal K intake associated with increased myelination and better neurocognitive...
JPM: Is the UK's Clinical Trials Sector Turning a Corner?
The UK medicines regulator reported a 9% rise in clinical trial applications year‑over‑year, with early‑stage studies leading the growth. Healthy‑volunteer and first‑in‑human trials increased 16% and 5% respectively, while sponsor requests for regulatory advice surged 75%. The MHRA announced a...
Open-Sourcing the Future of Food: New Cell Bank Makes Cultivated-Meat Tech Public
Tufts University's Center for Cellular Agriculture (TUCCA) and the Good Food Institute have purchased eight cultivated‑beef cell lines and serum‑free media from the defunct SciFi Foods. The assets, including CRISPR‑edited lines capable of indefinite growth in single‑cell suspension, will be...
Lactate Triggers GPR81/FARP1 for Insulin-Free Glucose Uptake
Researchers have identified that extracellular lactate activates the GPR81 receptor, which in turn engages the FARP1 signaling cascade to promote glucose uptake without insulin. The study demonstrated a 30% increase in glucose transport in muscle cells and a 20% boost...
Treg Biotech Sonoma Sheds Staff After Getting New CEO
Sonoma BioTherapeutics, a T‑regulatory cell biotech based in Sonoma, announced a workforce reduction across its Seattle, South San Francisco and remote positions following the appointment of a new chief executive officer. The cuts affect multiple departments as the company seeks...
Merck to Complete Acquisition of Cidara Therapeutics
Merck completed its cash tender offer to acquire Cidara Therapeutics, paying $221.50 per share. The offer was accepted for 27.15 million shares, representing about 86% of Cidara’s outstanding stock, and will be finalized through a merger making Cidara a wholly‑owned subsidiary....
Carvacrol and Chloroquine Synergistically Halt Melanoma Metastasis
Researchers have demonstrated that the natural compound carvacrol and the antimalarial drug chloroquine work synergistically to trigger apoptosis in metastatic melanoma cells. In vitro experiments showed markedly higher cell death when both agents were combined than when used alone, and...
Congress' Biotech Panel Pitches FDA Policy Upgrades to Help Performance
The National Security Commission on Emerging Biotechnology released a report urging the FDA to modernize its policies as biotech innovation outpaces regulation. The document proposes nearly two dozen specific reforms aimed at accelerating approvals while preserving safety. Recommendations include real‑time...
AbbVie, Amgen, Lilly Lead Calls for FDA To Update Post-Approval Change Rules
Big‑pharma leaders including AbbVie, Amgen and Eli Lilly urged the FDA to decouple pre‑approval inspections from marketing applications and modernize its post‑approval change framework. They argue the 1990s SUPAC guidance treats all biologics as high‑risk, slowing domestic facility transfers. The coalition...
At JPM26, Experts Try To Look Past the Most Favored Nation ‘Distraction’
At JPM26, life‑science investors and policymakers dissected the Trump administration’s disruptive biotech agenda. Health Secretary Robert F. Kennedy Jr. ordered the CDC to drop several childhood‑vaccine recommendations, unsettling billion‑dollar vaccine revenues. The administration’s focus on Most Favored Nation (MFN) drug‑pricing leverage spurred a...
JPM Lineup: New Roles Across Industry
Dozens of biotech firms and investors announced senior‑level moves ahead of the J.P. Morgan Healthcare Conference, with several companies naming new CEOs. At Argenx, co‑founder Tim Van Hauwermeiren is stepping down after 18 years to become chairman, while COO Karen Massey, a...
Gamma Rays Quickly Toughen Nitrogen‑fixing Bacteria
Researchers at Japan’s National Institutes for Quantum Science and Technology combined adaptive laboratory evolution with repeated gamma‑ray mutagenesis to create heat‑tolerant Bradyrhizobium diazoefficiens strains. By exposing cultures to stepwise temperature increases and ten 40 Gy irradiation rounds, they reduced development time...
Nine-Digit Venture Rounds for Mirador, Kinaset
Mirador Therapeutics announced a $120 million Series B round, while KinaseT secured $95 million in a Series A financing. Both rounds were led by top‑tier biotech investors including OrbiMed, ARCH Venture Partners and Sofinnova Partners. The capital will accelerate the companies' oncology and immunotherapy...
JPM Day 1: Big Bucks for Bispecific
AbbVie announced a $5.6 billion agreement with RemeGen to acquire rights to a bispecific antibody that simultaneously blocks PD‑1 and VEGF. The deal, disclosed at JPMorgan’s Day 1 event, provides RemeGen with a substantial upfront payment and ties future milestones to clinical...
Trenchant BioSystems Reports Multiple Data Readouts From AutoCell CGT Manufacturing Prototype
Trenchant Biosystems unveiled data from its AutoCell CGT manufacturing prototype, claiming a reduction of vein‑to‑vein timelines from six weeks to just 2.5 days. The platform reportedly delivers a seven‑fold increase in gene‑modified cell yield while cutting costs by up to...
New Early Stage VC Apuri Seeks to Seed China’s Academic Discoveries
Apuri, a new Shanghai‑based early‑stage venture firm, is launching its debut fund to commercialize biotech breakthroughs emerging from China’s academic labs. The firm is founded by three seasoned entrepreneurs whose backgrounds span biotech executive leadership, investment banking and venture capital....
Robotic Nanoprobe Enables Precise Extraction of a Single Mitochondrion From a Living Cell
Researchers at HKUST have unveiled an automated robotic nanoprobe that can locate and extract a single mitochondrion from a living cell without fluorescent labels. The device integrates nanoelectrodes that sense ROS/RNS bursts and dielectrophoretic nanotweezers that capture the organelle within...
Designer Enzyme Enables Yeast to Produce Custom Fatty Acids, Reducing Need for Palm Oil
A team led by Prof. Martin Grininger at Goethe University engineered a fatty‑acid synthase (FAS) enzyme that lets yeast synthesize custom short‑chain fatty acids, demonstrated with a 12‑carbon product normally sourced from palm or coconut oil. By swapping a single...
Pretzel Buys Rome and Its ‘Dark Genome’ Work
Pretzel Therapeutics announced the acquisition of Rome Therapeutics, a company specializing in “dark genome” research. The deal brings Rome’s functional genomics platform, extensive data sets, and scientific team under Pretzel’s AI‑driven drug discovery umbrella. Financial terms were not disclosed, but...
Nvidia-Partnered Startup Reveals AI-Generated Enzymes for Precise Gene Insertion
Basecamp Research, in partnership with Nvidia, unveiled a gene‑editing toolkit built from AI‑generated enzymes. The startup leveraged evolutionary deep‑learning models running on Nvidia GPUs to design proteins that insert DNA sequences with unprecedented precision. Early laboratory data indicate higher on‑target...
#JPM26: Novo Nordisk CEO Says Pharma Can Learn From the GLP-1 Compounding Boom
Novo Nordisk CEO Mike Doustad highlighted the explosive growth of telehealth‑driven GLP‑1 obesity drug sales. He noted that compounding pharmacies have rapidly scaled to meet demand, creating a new distribution model. Doustad argued that traditional pharma can learn from this...
Tracking Daily Mobility in Atypical Parkinsonian Patients
Researchers have deployed wearable sensors to continuously monitor daily mobility in patients with atypical Parkinsonian disorders. The study captured granular gait, step count, and activity‑level data over several weeks, revealing distinct movement signatures across disease subtypes. Findings show that reduced...
At FDA's Request, Pfizer Helps Ease Shortage of Potential Autism Drug
The U.S. Department of Health and Human Services confirmed that, at the FDA's request, Pfizer has been enlisted to help alleviate a nationwide shortage of a drug being promoted by Robert F. Kennedy Jr.'s organization as a potential autism treatment....
Compressed Data Technique Enables Pangenomics at Scale
Engineers at UC San Diego introduced PanMAN, a new data structure and compression format for pangenomics. PanMAN stores mutation‑annotated trees in a network, capturing phylogeny, recombination and whole‑genome alignments while representing each mutation only once. The approach achieves up to...
Cross-Species Links: Developmental Origins of Adult Hypersomnia
A new cross‑species study uncovers how early developmental disruptions predispose adults to hypersomnia. Researchers compared mouse, zebrafish, and human data, linking altered orexin signaling and circadian gene expression to chronic sleepiness. The analysis identified three molecular pathways—neuroinflammation, synaptic pruning deficits,...
